ProCE Banner Activity

CME

NASH: Evaluating Emerging Diagnostic and Treatment Strategies

Multimedia
In this on-demand Webcast, expert faculty review the latest diagnostic resources, emerging and investigational therapies, and strategies for improving the care of patients with NASH.

Physicians : maximum of 2.00 AMA PRA Category 1 {Credits}

Released: December 23, 2016

Expiration: December 22, 2017

No longer available for credit.

Share

Faculty

Stephen A. Harrison

Stephen A. Harrison, MD, MAJ (P), MC

Chief of Hepatology
Division of Gastroenterology and Hepatology
Brooke Army Medical Center
Fort Sam Houston, Texas

Quentin M. Anstee

Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP

Professor of Experimental Hepatology 
Consultant Hepatologist
Institute of Cellular Medicine
Newcastle University
Newcastle Upon Tyne, United Kingdom

Mary E. Rinella

Mary E. Rinella, MD

Associate Professor of Medicine
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Intercept Pharmaceuticals

Target Audience

This program is intended for physicians and other healthcare providers involved in the care of patients with NASH.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify patients who should undergo assessment for NAFLD/NASH
  • Utilize invasive and noninvasive tools to diagnose NASH and predict patient outcomes
  • Apply current best practices in the management of NASH, including lifestyle changes and pharmacologic therapies
  • Counsel patients on progress of investigational therapies for NASH, including mechanisms of action, safety, and hepatic efficacy outcomes

Program Director Disclosure

Program Director

Stephen A. Harrison, MD, MAJ (P), MC

Chief of Hepatology
Division of Gastroenterology and Hepatology
Brooke Army Medical Center
Fort Sam Houston, Texas

Stephen A. Harrison, MD, COL (Ret.), FAASLD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, the Chronic Liver Disease Foundation, FibroGen, Genfit, Intercept, Medivation, Merck, NGM Biopharmaceuticals, and Pfizer; has received fees for non-CME/CE services from AbbVie, Alexion, Gilead Sciences, and Merck; and funds for research support paid to his institution from Bristol-Myers Squibb, Conatus, Galectin, Galmed, Gilead Sciences, Immuron, Intercept, Madrigal, Merck, NGM Biopharmaceuticals, and Tobira.

Faculty Disclosure

Primary Author

Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP

Professor of Experimental Hepatology 
Consultant Hepatologist
Institute of Cellular Medicine
Newcastle University
Newcastle Upon Tyne, United Kingdom

Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP, has disclosed that he has received consulting fees paid to his institution from Acuitas Medical, Genfit, Intercept, Inventiva, Janssen, Lilly, NewGene, Pfizer, Raptor Pharmaceuticals, and Tobira and funds for research support paid to his institution from AbbVie and GlaxoSmithKline.

Mary E. Rinella, MD

Associate Professor of Medicine
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Mary E. Rinella, MD, has disclosed that she has received consulting fees from Amarin, BioPharma, Echosens, Enanta, Immuron, Intercept, NGM Biopharmaceuticals, and NuSirt.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran D. Mir-Hudgeons, PhD, has no real or apparent conflicts of interest to report.

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 23, 2016, through December 22, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ confidence and competence in diagnosing and managing patients with NASH, as well as to improve participants’ knowledge of emerging and investigational therapies for the management of NASH.